Prosecution Insights
Last updated: October 02, 2026
Application No. 18/469,762

CROSSLINKED RADIOPAQUE NETWORKS FOR MEDICAL APPLICATIONS

Final Rejection §DOUBLEPATENT
Filed
Sep 19, 2023
Priority
Sep 26, 2022 — provisional 63/410,154
Examiner
PACKARD, BENJAMIN J
Art Unit
1612
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Boston Scientific Corporation
OA Round
2 (Final)
67%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
82%
With Interview

Examiner Intelligence

Grants 67% — above average
67%
Career Allowance Rate
894 granted / 1341 resolved
+6.7% vs TC avg
Strong +16% interview lift
Without
With
+15.6%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
45 currently pending
Career history
1389
Total Applications
across all art units

Statute-Specific Performance

§101
2.2%
-37.8% vs TC avg
§103
47.9%
+7.9% vs TC avg
§102
16.1%
-23.9% vs TC avg
§112
15.6%
-24.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1341 resolved cases

Office Action

§DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Applicants' arguments, filed 06/09/2026, have been fully considered. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application. Upon consideration of Applicants argument, Examiner agrees that the required coupling is not taught in the prior art, and therefore the claims are found allowable over the prior art. Double Patenting Claims 1-20 stand are provisionally rejected on the grounds of nonstatutory double patenting as being unpatentable over claims of copending Applications Nos. 18/614,277 (reference application). Applicants request this rejection be held in abeyance; therefore it is maintained for reasons of record. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BENJAMIN J PACKARD whose telephone number is (571)270-3440. The examiner can normally be reached Mon 2-6pm and Tues-Fri 9:30am-6:30pm + mid-day flex. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sahana S. Kaup can be reached at (571) 272-6897. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BENJAMIN J PACKARD/ Primary Examiner, Art Unit 1612
Read full office action

Prosecution Timeline

Sep 19, 2023
Application Filed
Mar 09, 2026
Non-Final Rejection mailed — §DOUBLEPATENT
Jun 09, 2026
Response Filed
Aug 27, 2026
Final Rejection mailed — §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12746227
BENZIMIDAZOLE COMPOUND FOR THE TREATMENT OF METABOLIC DISORDERS
4y 0m to grant Granted Sep 29, 2026
Patent 12746296
IODINE LABELED HYDROGELS AND PRECURSORS THEREOF WITH IMPROVED RADIOPACITY
3y 11m to grant Granted Sep 29, 2026
Patent 12740933
WATER-IN-OIL EMULSION COSMETIC
2y 5m to grant Granted Sep 22, 2026
Patent 12740923
PHARMACEUTICAL FORMULATION
1y 8m to grant Granted Sep 22, 2026
Patent 12735581
ANTIFOULING COMPOUNDS
3y 5m to grant Granted Sep 15, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
67%
Grant Probability
82%
With Interview (+15.6%)
2y 11m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1341 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month